Dassault Systèmes agreed to acquire ArisGlobal for up to $2 billion, consisting of about $1.8 billion in cash at closing and up to $200 million in additional payments tied to AI-related revenue milestones, with the deal financed entirely from cash on hand. The transaction, unanimously approved by Dassault’s board and subject to regulatory approvals, is expected to close in the second half of 2026 and is anticipated to be accretive to revenue growth and EPS in year one. Management frames the acquisition as a boost to its AI strategy by integrating ArisGlobal’s life-sciences software with the 3DEXPERIENCE platform to support regulatory, safety, and modeling capabilities across drug development and pharmacovigilance. The move follows Dassault’s solid Q2 performance, with €1.56 billion in revenue, 4% growth in constant currency, strong cloud growth of 14%, and an annual run rate of €4.44 billion, reinforcing its full-year objectives. The deal positions Dassault to accelerate the digital transformation of the life-sciences sector by creating a unified AI platform that links molecule, patient, and real-world outcomes, continuing its expansion beyond traditional aerospace and automotive software. Overall, the acquisition signals a broader AI-native platform strategy and leverages the company’s Medidata heritage to deepen its healthcare technology ecosystem.